Meta intends to conduct a first wave of sweeping layoffs planned for this year on May 20, with more coming later, three sources familiar with the plans told Reuters. The Facebook and Instagram owner will lay off about 10% of its global workforce, or close to 8,000 employees, in that initial round, one of the sources said. The company is planning further layoffs in the second half of the year, t...
Meta intends to conduct a first wave of sweeping layoffs planned for this year on May 20, with more coming later, three sources familiar with the plans told Reuters. The Facebook and Instagram owner will lay off about 10% of its global workforce, or close to 8,000 employees, in that initial round, one of the sources said. The company is planning further layoffs in the second half of the year, the three sources said, although details of those cuts, including date and size, were not yet settled.
Does Trump Know Something We Don't About Potential SCOTUS Vacancies? Authored by Matt Margolis via PJMedia,com, The midterm elections are coming up in November, and Democrats are generally favored to win the House, while the Senate is kind of a coin flip. While it would suck for Democrats to win the House because they’ll almost certainly find some bogus pretext to impeach President Donald Trump, t...
Does Trump Know Something We Don't About Potential SCOTUS Vacancies? Authored by Matt Margolis via PJMedia,com, The midterm elections are coming up in November, and Democrats are generally favored to win the House, while the Senate is kind of a coin flip. While it would suck for Democrats to win the House because they’ll almost certainly find some bogus pretext to impeach President Donald Trump, there’s potentially more at stake regarding control of the Senate, including implications for confirming judges and potentially filling any potential Supreme Court vacancies. No retirements have been announced, but speculation is mounting, and I’m starting to wonder if Trump knows vacancies are coming. In a recent interview with Fox Business' Maria Bartiromo, Trump confirmed he has a shortlist of potential nominees ready to go — and he's prepared to fill as many as three seats if the opportunity arises. "In theory, it's two — you just read the statistics — it could be two, could be three, could be one," Trump said. "I don't know. I'm prepared to do it. But when you mention Alito, he is a great justice." He added, "He does what's right for the country. It's the law, and he goes by it as much as anybody, but he gets to the point." High praise from a president who has been, let's say, less enthusiastic about some of his own past nominees. According to Fox News Digital , " Trump's remarks sharpen the stakes around any potential vacancy, as the president has signaled he is ready to seize the opportunity to deepen the court’s conservative majority. With retirement speculation around Alito and Republicans eyeing the window before the 2026 midterms, the prospect of an opening is already putting fresh focus on succession politics." Rumors about Alito, 76, potentially retiring have grown because of his age, his two-decade tenure on the bench and speculation that he may want to make sure a conservative successor is confirmed by the current Republican-led Senate, especially before the u...
On Friday, the Dow Jones Industrial Average (^DJI) surged over 800 points, while both the S&P 500 (^GSPC) and Nasdaq Composite (^IXIC) gained over 1% each. Yahoo Finance Markets and Data Editor Jared Blikre takes a look at the week's biggest market moves, including action from the "Magnificent Seven" (MAGS), semiconductor sector (^SOX), software sector (IGV), CBOE Volatility Index (^VIX), 10-year ...
On Friday, the Dow Jones Industrial Average (^DJI) surged over 800 points, while both the S&P 500 (^GSPC) and Nasdaq Composite (^IXIC) gained over 1% each. Yahoo Finance Markets and Data Editor Jared Blikre takes a look at the week's biggest market moves, including action from the "Magnificent Seven" (MAGS), semiconductor sector (^SOX), software sector (IGV), CBOE Volatility Index (^VIX), 10-year Treasury yields (^TNX), the US dollar (DX-Y.NYB), bitcoin (BTC-USD), and more.
Social Security benefits are a reliable and important income source for seniors, but they absolutely cannot be your only source of funds in your later years. Once your paychecks stop coming in, you must be able to support yourself for the rest of your life, including paying for essentials like medical bills that increase as ... How much money do you need to supplement your Social Security Check?
Social Security benefits are a reliable and important income source for seniors, but they absolutely cannot be your only source of funds in your later years. Once your paychecks stop coming in, you must be able to support yourself for the rest of your life, including paying for essentials like medical bills that increase as ... How much money do you need to supplement your Social Security Check?
Getty Images In a surprising turn for the markets since the Iran conflict began, the S&P 500 has found footing at fresh new all-time highs. With the velocity of the rebound in the past few weeks, many investors are now asking, are there still buyable pockets left in the market? I still find vast appeal in rebound plays, particularly in the software and retail stocks that have fallen hard this year...
Getty Images In a surprising turn for the markets since the Iran conflict began, the S&P 500 has found footing at fresh new all-time highs. With the velocity of the rebound in the past few weeks, many investors are now asking, are there still buyable pockets left in the market? I still find vast appeal in rebound plays, particularly in the software and retail stocks that have fallen hard this year. Within retail, I believe lululemon athletica inc. ( LULU ), the activewear company that has been struggling with maintaining share in the United States, is appealing after a ~20% decline since the start of the year. Data by YCharts I last wrote a "Buy" article on lululemon in January, when the stock was trading just north of $200 per share. While the timing on my buy call was premature, my conviction in the stock remains high, especially after a favorable recent Q4 earnings print that demonstrates the company understands what its issues are and has a plan in place to resolve performance issues. I’m reiterating my "Buy" rating here. To me, these are the core reasons to be long on lululemon: Reigniting product innovation to return to full-price sales. One of lululemon’s core issues has been stale product, which has led to clearance sales of slow-moving seasonal inventory that damaged not only the company’s gross margins but also the prestige of its brand. The company has released new high-performance training materials, including a new men’s/women’s lineup called Unrestricted Power using new lightweight stretchy materials. Fierce international growth. Even though lululemon’s U.S. sales have been stagnant, the company has been achieving accelerating performance overseas. International is growing at a 20%+ clip, powered by new markets including South Korea. Relatively high gross margins. Though lululemon has been battered by tariffs, the company still maintains a rich mid-50s gross margin profile that enables economies of scale. The potential rollback of tariffs is a further ...
arlutz73/iStock Editorial via Getty Images Investment Thesis Among the broad-cap stocks of the U.S. stock exchange, Bristol-Myers Squibb (NYSE: BMY) is the most vulnerable to mispricing. Both Eliquis and Opdivo lose exclusivity in 2028 and 2029, respectively, and the loss of exclusivity is well documented. All analysts have modeled the risk of the stock, and this has become a widely discussed topi...
arlutz73/iStock Editorial via Getty Images Investment Thesis Among the broad-cap stocks of the U.S. stock exchange, Bristol-Myers Squibb (NYSE: BMY) is the most vulnerable to mispricing. Both Eliquis and Opdivo lose exclusivity in 2028 and 2029, respectively, and the loss of exclusivity is well documented. All analysts have modeled the risk of the stock, and this has become a widely discussed topic. Despite the current P/E of 8.9x, the market has priced in a scenario in which the company is unable to replace its revenue. Opdualag, Breyanzi, Camzyos, Reblozyl, and Cobenfy are the Growth Portfolio. These and some other newer drugs delivered $26.4 billion in revenue in FY2025, grew 17% year-over-year, and are guided to continue double-digit growth in 2026—implying that the market is wrong regarding revenue replacement. The key financial facts come directly from the Bristol-Myers Squibb Q4 2025 8-K filed with the SEC on February 5, 2026 . Full-year 2025 revenue was $48.2 billion. Growth Portfolio revenue was $26.4 billion, up 17% year-over-year. Non-GAAP EPS was $6.15. The management estimates 2026 guidance of $46.0–$47.5 billion in revenue coupled with non-GAAP EPS of $6.05–$6.35, which is an improved performance compared to the previous analysts' forecast. The company has announced its 17th consecutive quarterly dividend increase. Nonetheless, BMY trades at approximately 8.9x forward earnings, the lowest it has been relative to large-cap pharmaceutical counterparts in a decade. The patent cliff is real, and the revenue impact will be tangible—nobody serious is disputing that. What the consensus has missed is that two years of pricing in that fear has pushed BMY to a level where the Growth Portfolio alone, stripped of any pipeline optionality, may already cover the entire current market capitalization. That is not a contrarian bet against the risk. It is a recognition that the risk has been so thoroughly priced that the stock is now offering the upside for free. BMY gr...
da-kuk/iStock via Getty Images Rebounding quickly after the conflict in Iran began, the S&P 500 is now sitting at fresh all-time highs. Many investors, such as myself, are newly concerned about valuation, as the major indices sit at expensive multiples considering the vast uncertainty that still hangs over the macro: unsolved geopolitical tensions, a cooldown in the macroeconomy, and the beginning...
da-kuk/iStock via Getty Images Rebounding quickly after the conflict in Iran began, the S&P 500 is now sitting at fresh all-time highs. Many investors, such as myself, are newly concerned about valuation, as the major indices sit at expensive multiples considering the vast uncertainty that still hangs over the macro: unsolved geopolitical tensions, a cooldown in the macroeconomy, and the beginning of AI-driven layoffs. But pockets of value still exist in the market, primarily in the small/mid-cap software space that has been decimated by the "SaaSpocalypse." Instead of being at all-time highs, these stocks are in a bear market at multi-year lows. Appian ( APPN ), a business process management software company, has been particularly hard hit, with its shares down nearly 40% year to date. Data by YCharts I last wrote a buy article on Appian in November, when the stock was trading in the low $40s. Needless to say, the timing of my buy call was off, and I didn't predict the "SaaSpocalypse" that would drive an indiscriminate selloff across the software sector. I find Appian to be a beneficiary, not at-risk from AI: and when taking a look at the stock with fresh eyes, I see no red flags in the company's execution. I'm reiterating my buy rating on this name. For investors who are newer to Appian, here is my long-term bull case on the company: All indications point to AI tailwinds for Appian. The company has noted that AI-related traffic has been driving increased workflows for the company while also driving higher average subscription prices. Appian's core thesis is that in order for AI to drive value, businesses first need to identify process frameworks that AI can eventually automate, and the company's recent improvement in subscription retention rates is a clear indication that this thesis is playing out. Expanding more deeply into federal deals. Appian's Government Cloud has achieved FedRAMP certification, enabling it to become a government vendor. The company has rece...
Bloomberg's Katherine Doherty and Olivia Fishlow joins Katie Greifeld on "Bloomberg Real Yield." For years, Wall Street banks eagerly helped private credit funds amplify their investing firepower with hundreds of billions of dollars in loans. Now, those same banks are tightening their arrangements, adding to the pressure on managers already reeling from an exodus of investors. (Source: Bloomberg)
Bloomberg's Katherine Doherty and Olivia Fishlow joins Katie Greifeld on "Bloomberg Real Yield." For years, Wall Street banks eagerly helped private credit funds amplify their investing firepower with hundreds of billions of dollars in loans. Now, those same banks are tightening their arrangements, adding to the pressure on managers already reeling from an exodus of investors. (Source: Bloomberg)